Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
Identifieur interne : 001391 ( PubMed/Corpus ); précédent : 001390; suivant : 001392Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
Auteurs : Simon Lemay ; Sylvain Chouinard ; Pierre Blanchet ; Hélène Masson ; Valérie Soland ; Anne Beuter ; Marc-André BédardSource :
- Progress in neuro-psychopharmacology & biological psychiatry [ 0278-5846 ] ; 2004.
English descriptors
- KwdEn :
- Administration, Cutaneous, Aged, Biomechanical Phenomena, Cognition Disorders (drug therapy), Cognition Disorders (etiology), Female, Humans, Male, Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Neuropsychological Tests, Nicotine (administration & dosage), Nicotine (blood), Nicotine (therapeutic use), Nicotinic Agonists (administration & dosage), Nicotinic Agonists (blood), Nicotinic Agonists (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Psychomotor Performance (drug effects), Reaction Time (drug effects), Verbal Learning (drug effects).
- MESH :
- chemical , administration & dosage : Nicotine, Nicotinic Agonists.
- chemical , blood : Nicotine, Nicotinic Agonists.
- complications : Parkinson Disease.
- drug effects : Psychomotor Performance, Reaction Time, Verbal Learning.
- drug therapy : Cognition Disorders, Movement Disorders, Parkinson Disease.
- etiology : Cognition Disorders, Movement Disorders.
- chemical , therapeutic use : Nicotine, Nicotinic Agonists.
- Administration, Cutaneous, Aged, Biomechanical Phenomena, Female, Humans, Male, Middle Aged, Neuropsychological Tests.
Abstract
Studies assessing the efficacy of nicotine in Parkinson's disease (PD) have generated contradictory results. The controversy seems to stem from uncontrolled factors including the lack of objective measures, the practice effect in a test-retest design, and the absence of plasmatic dosage. This study aimed at further controlling these factors using transdermal nicotine in PD.
DOI: 10.1016/S0278-5846(03)00172-6
PubMed: 14687854
Links to Exploration step
pubmed:14687854Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.</title><author><name sortKey="Lemay, Simon" sort="Lemay, Simon" uniqKey="Lemay S" first="Simon" last="Lemay">Simon Lemay</name><affiliation><nlm:affiliation>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name></author><author><name sortKey="Blanchet, Pierre" sort="Blanchet, Pierre" uniqKey="Blanchet P" first="Pierre" last="Blanchet">Pierre Blanchet</name></author><author><name sortKey="Masson, Helene" sort="Masson, Helene" uniqKey="Masson H" first="Hélène" last="Masson">Hélène Masson</name></author><author><name sortKey="Soland, Valerie" sort="Soland, Valerie" uniqKey="Soland V" first="Valérie" last="Soland">Valérie Soland</name></author><author><name sortKey="Beuter, Anne" sort="Beuter, Anne" uniqKey="Beuter A" first="Anne" last="Beuter">Anne Beuter</name></author><author><name sortKey="Bedard, Marc Andre" sort="Bedard, Marc Andre" uniqKey="Bedard M" first="Marc-André" last="Bédard">Marc-André Bédard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14687854</idno><idno type="pmid">14687854</idno><idno type="doi">10.1016/S0278-5846(03)00172-6</idno><idno type="wicri:Area/PubMed/Corpus">001391</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001391</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.</title><author><name sortKey="Lemay, Simon" sort="Lemay, Simon" uniqKey="Lemay S" first="Simon" last="Lemay">Simon Lemay</name><affiliation><nlm:affiliation>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name></author><author><name sortKey="Blanchet, Pierre" sort="Blanchet, Pierre" uniqKey="Blanchet P" first="Pierre" last="Blanchet">Pierre Blanchet</name></author><author><name sortKey="Masson, Helene" sort="Masson, Helene" uniqKey="Masson H" first="Hélène" last="Masson">Hélène Masson</name></author><author><name sortKey="Soland, Valerie" sort="Soland, Valerie" uniqKey="Soland V" first="Valérie" last="Soland">Valérie Soland</name></author><author><name sortKey="Beuter, Anne" sort="Beuter, Anne" uniqKey="Beuter A" first="Anne" last="Beuter">Anne Beuter</name></author><author><name sortKey="Bedard, Marc Andre" sort="Bedard, Marc Andre" uniqKey="Bedard M" first="Marc-André" last="Bédard">Marc-André Bédard</name></author></analytic><series><title level="j">Progress in neuro-psychopharmacology & biological psychiatry</title><idno type="ISSN">0278-5846</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Biomechanical Phenomena</term><term>Cognition Disorders (drug therapy)</term><term>Cognition Disorders (etiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Neuropsychological Tests</term><term>Nicotine (administration & dosage)</term><term>Nicotine (blood)</term><term>Nicotine (therapeutic use)</term><term>Nicotinic Agonists (administration & dosage)</term><term>Nicotinic Agonists (blood)</term><term>Nicotinic Agonists (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Psychomotor Performance (drug effects)</term><term>Reaction Time (drug effects)</term><term>Verbal Learning (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nicotine</term><term>Nicotinic Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Nicotine</term><term>Nicotinic Agonists</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Psychomotor Performance</term><term>Reaction Time</term><term>Verbal Learning</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nicotine</term><term>Nicotinic Agonists</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Biomechanical Phenomena</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies assessing the efficacy of nicotine in Parkinson's disease (PD) have generated contradictory results. The controversy seems to stem from uncontrolled factors including the lack of objective measures, the practice effect in a test-retest design, and the absence of plasmatic dosage. This study aimed at further controlling these factors using transdermal nicotine in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14687854</PMID><DateCreated><Year>2003</Year><Month>12</Month><Day>22</Day></DateCreated><DateCompleted><Year>2004</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology & biological psychiatry</Title><ISOAbbreviation>Prog. Neuropsychopharmacol. Biol. Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>31-9</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Studies assessing the efficacy of nicotine in Parkinson's disease (PD) have generated contradictory results. The controversy seems to stem from uncontrolled factors including the lack of objective measures, the practice effect in a test-retest design, and the absence of plasmatic dosage. This study aimed at further controlling these factors using transdermal nicotine in PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-two nonsmoking PD patients received a transdermal nicotine treatment over 25 days in increasing titrated doses. Motor and cognitive assessments were carried out on days 11 and 25 (low-dose and high-dose assessments, respectively) and after a 14-day washout period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients tolerated nicotine poorly. Thirteen (59%) withdrew, mostly because of acute side effects. In the remaining nine patients, nicotine neither improved nor worsened motor or cognitive functioning in comparison with 10 age, gender and education matched controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Transdermal nicotine is not effective in treating motor and cognitive deficits in PD. The results obtained with our objective measures confirm a recent double-blind, placebo-controlled study that used clinical measures. It is possible that nicotine lacks specificity in targeting critical nicotinic receptors that might be involved in PD pathophysiology. The low tolerability may be related to such a lack of specificity of nicotine, which would directly stimulate the autonomic nervous system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lemay</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouinard</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Blanchet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>Hélène</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Soland</LastName><ForeName>Valérie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Beuter</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bédard</LastName><ForeName>Marc-André</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018722" MajorTopicYN="N">Nicotinic Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14687854</ArticleId><ArticleId IdType="pii">S0278-5846(03)00172-6</ArticleId><ArticleId IdType="doi">10.1016/S0278-5846(03)00172-6</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001391 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001391 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:14687854
|texte= Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:14687854" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |